What Happened

A registered nurse at a Massachusetts rehabilitation center was sentenced in federal court in Boston to 15 months in prison and three years of supervised release for drug tampering. In October 2020 she had pleaded guilty to one count of tampering with a consumer product, specifically the Schedule II controlled substance oxycodone.

While working as a registered nurse at Dighton Care and Rehabilitation Center, the nurse tampered with three blister card packages of oxycodone prescribed to an 89-year-old hospice patient who had Alzheimer's disease, severe dementia and breast cancer. To avoid detection, she replaced the stolen oxycodone pills with other prescription drugs disguised to look like oxycodone.

The patient was deprived of her prescribed oxycodone for at least a month and ingested at least 77 unnecessary prescription tablets. U.S. District Judge Indira Talwani imposed the sentence on December 20, 2021. The announcement came from the Acting U.S. Attorney for the District of Massachusetts together with the FDA Office of Criminal Investigations, the Office of Inspector General of the Department of Health and Human Services, and the Massachusetts Department of Public Health, and the case was prosecuted by the office's Health Care Fraud Unit.

“replaced the stolen oxycodone pills with other prescription drugs disguised to look like oxycodone”

U.S. Department of Justice / U.S. Attorney's Office press release, Dec 20, 2021

What the Release Does Not Say

The release does not say how the diversion was discovered, how long the nurse had worked at the center, or what controls the center had in place. It does not say whether the center was disciplined. The facts below are limited to what the release states: whose medication was taken, how it was taken, what replaced it, and what the patient took as a result.

The Pattern Worth Recognizing

This is a substitution case rather than a missing-count case. The pills were replaced with look-alikes, so a count of tablets in the blister cards would not by itself have shown a shortage. The harm in the release is to the patient, who went without prescribed pain relief for at least a month while taking drugs that had not been prescribed for that purpose. These checks speak to that pattern in general:

  • Inspect patient-specific blister cards for identity, not just count: imprint, colour and shape against the product that was dispensed.
  • Treat a hospice or long-term-care patient whose pain is unexpectedly uncontrolled as a possible diversion signal and review the medication supply, not only the dose. See 15 Red Flags of Drug Diversion.
  • Have a defined route for a nurse, aide or family member to report concerns about a patient's medication supply, and follow it with an inspection of the packaging.

Related Guidance

Sources